FGFR2 and neoplasm: Using FGFR2b isoform-specific antibodies, several studies have demonstrated that FGFR2b overexpression assessed by immunohistochemistry correlates with FGFR2 amplification, indicating that it is the predominant isoform expressed in these tumours, and also suggesting that it could be used as a cost-effective screening test to detect FGFR2 amplification [43,44].